title: Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?
authors.forename: U
authors.initials: U
authors.lastname: Jacobi
authors.forename: E
authors.initials: E
authors.lastname: Waibler
authors.forename: P
authors.initials: P
authors.lastname: Schulze
authors.forename: J
authors.initials: J
authors.lastname: Sehouli
authors.forename: G
authors.initials: G
authors.lastname: Oskay-Ozcelik
authors.forename: T
authors.initials: T
authors.lastname: Schmook
authors.forename: W
authors.initials: W
authors.lastname: Sterry
authors.forename: J
authors.initials: J
authors.lastname: Lademann
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000032:analysis*; D004317:Doxorubicin / Q000032:analysis* / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012871:Skin Diseases / Q000139:chemically induced*; D013542:Sweat / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin